ViolaWeijiaZhuMDPhD

PubMed

• 6 citations
  The Role of Chemotherapy Plus Immune Checkpoint Inhibitors in Oncogenic-Driven NSCLC: A University of California Lung Cancer Consortium Retrospective Study.
  David J Benjamin, Shuai Chen, Joanna B Eldredge, Shiruyeh Schokrpur, Debory Li, Zhikuan Quan, Jason W Chan, Amy L Cummings, Megan E Daly, Jonathan W Goldman, Matthew A...> ;JTO Clinical and Research Reports. 2022 Dec 1
• 22 citations
  Sunvozertinib, a Selective EGFR Inhibitor for Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations.
  Mengzhao Wang, James Chih-Hsin Yang, Paul L Mitchell, Jian Fang, D Ross Camidge, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, Tsung-Ying Yang, Vi...> ;Cancer Discovery. 2022 Jul 6
• 17 citations
  Hypersensitivity Reactions to Selpercatinib Treatment With or Without Prior Immune Checkpoint Inhibitor Therapy in Patients With NSCLC in LIBRETTO-001.
  Caroline E McCoach, Christian Rolfo, Alexander Drilon, Mario Lacouture, Benjamin Besse, Koichi Goto, Viola W Zhu, Daniel S W Tan, Stephanie Farajian, Laura A Potter, J...> ;Journal of Thoracic Oncology. 2022 Jun 1
• 24 citations
  INSIGHT 2: a phase II study of tepotinib plus osimertinib in-amplified NSCLC and first-line osimertinib resistance.
  Egbert F Smit, Christophe Dooms, Jo Raskin, Ernest Nadal, Lye M Tho, Xiuning Le, Julien Mazieres, How S Hin, Masahire Morise, Viola W Zhu, Daniel Tan, Kristina H Holmb...> ;Future Oncology. 2022 Mar 1
• 53 citations
  Efficacy of Aumolertinib (HS-10296) in Patients with Advanced EGFR T790M+ NSCLC: Updated Post NMPA-approval Results from the APOLLO Registrational Trial
  Shun Lu, Qiming Wang, Guojun Zhang, Xiaorong Dong, Cheng-Ta Yang, Yong Song, Gee-Chen Chang, You Lu, Hongming Pan, Chao-Hua Chiu, Zhehai Wang, Jifeng Feng, Jianying Zh...> ;Journal of Thoracic Oncology. 2021 Nov 18
• Ensartinib (X-396), an Approved ALK Inhibitor, Falls Out as a Clinically Relevant ROS1 Inhibitor.
  Viola W. Zhu, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2021 Nov 1
• 20 citations
  Will the clinical development of 4th-generation “double mutant active” ALK TKIs (TPX-0131 and NVL-655) change the future treatment paradigm of ALK+ NSCLC?
  Sai-Hong Ignatius Ou, Misako Nagasaka, Danielle Brazel, Yujie Hou, Viola W. Zhu> ;Translational Oncology. 2021 Nov 1
• 134 citations
  Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1/2 study
  Vivek Subbiah, Mimi I. Hu, Lori J. Wirth, Martin Schuler, Aaron S. Mansfield, Giuseppe Curigliano, Marcia S. Brose, Viola W. Zhu, Sophie Leboulleux, Daniel W. Bowles, ...> ;The Lancet. Diabetes & Endocrinology. 2021 Aug 1
• 10 citations
  Spotlight on Mobocertinib (TAK-788) in NSCLC with EGFR Exon 20 Insertion Mutations
  Viola W. Zhu> ;Lung Cancer. 2021 Jul 12
• 166 citations
  Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
  Justin F. Gainor, Giuseppe Curigliano, Dong Wan Kim, Dae Ho Lee, Benjamin Besse, Christina S. Baik, Robert C. Doebele, Philippe A. Cassier, Gilberto Lopes, Daniel Shao...> ;The Lancet. Oncology. 2021 Jul 1
• 12 citations
  Acquired Tertiary MET Resistance (MET D1228N and a Novel LSM8-MET Fusion) to Selpercatinib and Capmatinib in a Patient With KIF5B-RET-positive NSCLC With Secondary MET...
  Viola W. Zhu, Jian Zhang, Jeffrey Swensen, Joanne Xiu, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2021 Jul 1
• 14 citations
  Response to Immune Checkpoint Inhibition as Monotherapy or in Combination With Chemotherapy in Metastatic ROS1-Rearranged Lung Cancers.
  Noura J. Choudhury, Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang, Christina Falcon, Andrew Do, Yunan Nie, Andrew J. Plodkowski, Jamie...> ;JTO Clinical and Research Reports. 2021 Jul 1
• 118 citations
  Activity and Safety of Mobocertinib (TAK-788) in Previously Treated Non-Small Cell Lung Cancer with EGFR Exon 20 Insertion Mutations from a Phase I/II Trial.
  Gregory J. Riely, Joel W. Neal, D. Ross Camidge, Alexander I. Spira, Zofia Piotrowska, Daniel B. Costa, Anne S. Tsao, Jyoti D. Patel, Shirish M. Gadgeel, Lyudmila Bazh...> ;Cancer Discovery. 2021 Jul 1
• 204 citations
  Acquired Resistance to KRASG12C Inhibition in Cancer
  Mark M. Awad, Shengwu Liu, Igor I. Rybkin, Kathryn C. Arbour, Julien Dilly, Viola W. Zhu, Melissa Lynne Johnson, Rebecca S. Heist, Tejas Patil, Gregory J. Riely, Josep...> ;The New England Journal of Medicine. 2021 Jun 23
• 46 citations
  Going beneath the tip of the iceberg. Identifying and understanding EML4-ALK variants and TP53 mutations to optimize treatment of ALK fusion positive (ALK+) NSCLC.
  Shannon S. Zhang, Misako Nagasaka, Viola W. Zhu, Sai-Hong Ignatius Ou> ;Lung Cancer. 2021 Jun 12
• 26 citations
  Clinicopathologic Features and Response to Therapy of NRG1 Fusion-Driven Lung Cancers: The eNRGy1 Global Multicenter Registry.
  Alexander Drilon, Michael Duruisseaux, Ji Youn Han, Masaoki Ito, Christina Falcon, Soo-Ryum Yang, Yonina R. Murciano-Goroff, Haiquan Chen, Morihito Okada, Miguel Angel...> ;Journal of Clinical Oncology. 2021 Jun 2
• 21 citations
  Thromboembolism in ALK+ and ROS1+ NSCLC patients: A systematic review and meta-analysis.
  Viola W. Zhu, Joseph J. Zhao, Yanfei Gao, Nicholas Syn, Sai-Hong Ignatius Ou, Kenneth A. Bauer, Misako Nagasaka> ;Lung Cancer. 2021 May 20
• 47 citations
  Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion–Positive Lung Cancer
  Jessica J. Lin, Noura J. Choudhury, Satoshi Yoda, Viola W. Zhu, Ted William Johnson, Ramin Sakhtemani, Ibiayi Dagogo-Jack, Subba R. Digumarthy, Charlotte E. Lee, Andre...> ;Clinical Cancer Research. 2021 May 15
• 8 citations
  Identification of Novel CDH1-NRG2α and F11R-NRG2α Fusions in NSCLC Plus Additional Novel NRG2α Fusions in Other Solid Tumors by Whole Transcriptome Sequencing
  Sai-Hong Ignatius Ou, Joanne Xiu, Misako Nagasaka, Bing Xia, Qing Zhang, Jeffrey Swensen, David Spetzler, Wolfgang Michael Korn, Viola W. Zhu, Stephen V. Liu> ;JTO Clinical and Research Reports. 2021 Feb 1
• 16 citations
  A Novel Sequentially Evolved EML4-ALK Variant 3 G1202R/S1206Y Double Mutation In Cis Confers Resistance to Lorlatinib: A Brief Report and Literature Review.
  Viola W. Zhu, Misako Nagasaka, Russell Madison, Alexa B. Schrock, Jean Cui, Sai-Hong Ignatius Ou> ;JTO Clinical and Research Reports. 2021 Jan 1
• 83 citations
  Beyond Osimertinib: The Development of Third-Generation EGFR Tyrosine Kinase Inhibitors For Advanced EGFR+ NSCLC.
  Misako Nagasaka, Viola W. Zhu, Sun Min Lim, Michael Greco, Fengying Wu, Sai-Hong Ignatius Ou> ;Journal of Thoracic Oncology. 2020 Dec 15
• 1 citations
  The Next Target for NSCLC: Let It Be "RET".
  Beung-Chul Ahn, Viola W. Zhu, Sun Min Lim> ;Journal of Thoracic Oncology. 2020 Dec 1
• 116 citations
  Mechanisms of resistance to selective RET tyrosine kinase inhibitors in RET fusion-positive non-small-cell lung cancer
  Jessica J. Lin, Stephen V. Liu, Caroline E. McCoach, Viola W. Zhu, Aaron C. Tan, Satoshi Yoda, Jennifer L Peterson, Andrew Do, Kylie Prutisto-Chang, Ibiayi Dagogo-Jack...> ;Annals of Oncology. 2020 Dec 1
• 38 citations
  Molecular Landscape of BRAF-Mutant NSCLC Reveals an Association Between Clonality and Driver Mutations and Identifies Targetable Non-V600 Driver Mutations
  Marcelo V. Negrao, Victoria M. Raymond, Richard B. Lanman, Jacqulyne P. Robichaux, Junqin He, Monique B. Nilsson, Patrick Kwok Shing Ng, Bianca E. Amador, Emily Roarty...> ;Journal of Thoracic Oncology. 2020 Oct 1
• 49 citations
  U.S. Phase I First-in-human Study of Taletrectinib (DS-6051b/AB-106), a ROS1/TRK Inhibitor, in Patients with Advanced Solid Tumors.
  Kyriakos P. Papadopoulos, Erkut Borazanci, Alice T. Shaw, Ryohei Katayama, Yuki Shimizu, Viola W. Zhu, Thomas Yang Sun, Heather A. Wakelee, Russell Madison, Alexa B. S...> ;Clinical Cancer Research. 2020 Sep 15
• Join now to see all

Journal Articles

• Efficacy of Selpercatinib in RET-Altered Thyroid Cancers  
  Lori J Wirth, Jochen Lorch, Francis Worden, Marcia Brose, Taofeek K Owonikoko, Mark E Burkard, Todd M Bauer, Viola W Zhu, Nehal Lakhani, Victor Moreno, Manisha H Shah, New England Journal of Medicine
• Severe Acute Hepatitis in a Patient Receiving Alectinib for ALK+ Non-Small Cell Lung Cancer: A Histological Analysis  
  Viola Zhu, MD, Clinical Lung Cancer